Denali Therapeutics (NASDAQ:DNLI – Get Free Report) and Absci (NASDAQ:ABSI – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.
Earnings and Valuation
This table compares Denali Therapeutics and Absci”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Denali Therapeutics | $3.60 million | 792.58 | -$512.54 million | ($2.84) | -6.29 |
| Absci | $2.80 million | 535.67 | -$115.18 million | ($0.80) | -10.92 |
Profitability
This table compares Denali Therapeutics and Absci’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Denali Therapeutics | N/A | -55.27% | -44.24% |
| Absci | -7,756.38% | -61.71% | -54.52% |
Risk and Volatility
Denali Therapeutics has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Absci has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Denali Therapeutics and Absci, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Denali Therapeutics | 1 | 2 | 13 | 0 | 2.75 |
| Absci | 1 | 0 | 9 | 0 | 2.80 |
Denali Therapeutics presently has a consensus target price of $35.85, suggesting a potential upside of 100.59%. Absci has a consensus target price of $13.88, suggesting a potential upside of 58.75%. Given Denali Therapeutics’ higher probable upside, research analysts clearly believe Denali Therapeutics is more favorable than Absci.
Institutional & Insider Ownership
92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Denali Therapeutics beats Absci on 9 of the 14 factors compared between the two stocks.
About Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson’s disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
